HongKong:3681

SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"

Retrieved on: 
星期一, 十二月 19, 2022
Clinical trial, The Company, Neuromyelitis optica spectrum disorder, Multiple sclerosis, FV, Antigen, B-cell lymphoma, The Group, State, National Medical Products Administration, Sjögren syndrome, Research, Rheumatoid arthritis, MS, Penumbra (medical company), SM03, Barakat Pharmaceutical Group, Death, Republic, NHL, NMPA, Alzheimer's disease, NDA, Mab, R, FIH, Sino Biopharmaceutical Limited, Patient, Attention, Degenerative disease, RA, NMOSD, Safety, BCR, Therapy, State Council, IND, SLE, Pemphigus, Immune system, Phase, AD, Central China, CD22, Pharmaceutical industry, Vaccine

SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.

Key Points: 
  • SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.
  • SinoMab is the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics, primarily monoclonal antibody ("mAb")-based biologics, for the treatment of immunological diseases.
  • Currently, various candidate products for all-field indications of autoimmune diseases in SinoMab's layout have started clinical trials successively and are progressing steadily.
  • Previously, SinoMab appointed Mr. Shanchun WANG as the President (China) of the Company, mainly responsible for the China operation.